Pustotina Olga
a Department of Obstetrics, Gynecology and Perinatology , Peoples' Friendship University of Russia , Moscow , Russian Federation.
J Matern Fetal Neonatal Med. 2018 Jul;31(14):1830-1838. doi: 10.1080/14767058.2017.1330406. Epub 2017 May 29.
To compare the efficacy of dydrogesterone, 17-OH progesterone (17OHP) and oral or vaginal micronized progesterone with cerclage for the prevention of preterm birth in women with a short cervix.
The study included 95 women with singleton gestation and cervical length (CL) ≤ 25 mm. Among these, 35 women were asymptomatic at 15-24 weeks and 60 had symptoms of threatened late miscarriage (LM) or preterm delivery (PD) at 15-32 weeks. Patients were randomized to receive dydrogesterone, 17OHP or oral/vaginal micronized progesterone; after one week of therapy 15 women underwent cerclage.
Efficacy of vaginal progesterone (VP) for the prevention of preterm birth reached 94.1%. In asymptomatic women pregnancy outcomes were comparable to cerclage. In women with threatened LM/PD, combination therapy with VP, indomethacin and treatment of bacterial vaginosis (BV) with the subsequent use VP until 36 weeks together with CL monitoring significantly decreased the rate of preterm birth (RR 0.01; 0.0001-0.24) and low birth weight (LBW) (RR 0.04; 0.01-0.96). CL increase during the first week of treatment with a subsequent plateau phase indicated treatment efficacy. Dydrogesterone, 17OHP, and micronized oral progesterone (OP) were associated with PD in 91.7% of women.
Combination management strategy including VP significantly benefits pregnancy outcomes in women with a short cervix compared with cerclage. Dydrogesterone, 17OHP, and OP were not found to be efficacious.
比较地屈孕酮、17-羟孕酮(17OHP)以及口服或阴道用微粒化孕酮与宫颈环扎术预防宫颈短的女性早产的疗效。
该研究纳入了95名单胎妊娠且宫颈长度(CL)≤25mm的女性。其中,35名女性在孕15 - 24周时无症状,60名在孕15 - 32周时有晚期流产(LM)或早产(PD)的先兆症状。患者被随机分为接受地屈孕酮、17OHP或口服/阴道用微粒化孕酮治疗;治疗一周后,15名女性接受了宫颈环扎术。
阴道用孕酮(VP)预防早产的疗效达94.1%。在无症状女性中,妊娠结局与宫颈环扎术相当。在有LM/PD先兆的女性中,VP、吲哚美辛联合治疗以及细菌性阴道病(BV)治疗,随后持续使用VP至36周并监测CL,显著降低了早产率(RR 0.01;0.0001 - 0.24)和低出生体重(LBW)率(RR 0.04;0.01 - 0.96)。治疗第一周CL增加,随后进入平台期,表明治疗有效。地屈孕酮、17OHP和微粒化口服孕酮(OP)使91.7%的女性发生PD。
与宫颈环扎术相比,包括VP的联合管理策略对宫颈短的女性妊娠结局有显著益处。未发现地屈孕酮、17OHP和OP有效。